SCHEDULE: Silo Pharma: Intracoastal Capital Discloses 9.99% Stake
Beneficial Ownership Disclosure
Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, disclosed a 9.99% beneficial ownership stake in Silo Pharma, Inc., primarily through warrant holdings.
Summary
- Reporting Persons Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively hold beneficial ownership of 838,081 shares of Silo Pharma, Inc. common stock.
- This represents 9.99% of the company's common stock.
- The ownership is primarily derived from the exercisable portions of Intracoastal Warrant 1 (833,334 shares) and Intracoastal Warrant 2 (4,747 shares).
- The calculation of the 9.99% stake is based on 7,207,792 shares outstanding as of May 16, 2025, plus 343,334 shares previously issued from a warrant exercise, and the 838,081 shares from the currently reported warrants.
- The reporting persons also hold additional warrants (Intracoastal Warrant 2, 3, and 4) with blocker provisions that prevent exercise beyond certain ownership thresholds (9.99% or 4.99%), which if fully exercisable, would result in beneficial ownership of 2,392,524 shares.
- The filing states the securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.
Positives
- NA This filing is a Schedule 13G, which is a disclosure of beneficial ownership and does not typically contain positive financial or operational outcomes.
Negatives
- NA This filing is a Schedule 13G, which is a disclosure of beneficial ownership and does not typically contain negative financial or operational outcomes.
Risks
- NA This filing is a Schedule 13G, which is a disclosure of beneficial ownership and does not typically detail company-specific risks.
Future Outlook
NA This filing is a Schedule 13G and does not provide a future outlook.
Management Comments
- NA This filing is a Schedule 13G and does not contain management comments.
Industry Context
NA This filing is a Schedule 13G and does not provide industry context.
Comparison to Industry Standards
- NA This filing is a Schedule 13G and does not provide comparisons to industry standards.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA This filing is a Schedule 13G and does not report legal proceedings.
Related Party Transactions
- NA This filing is a Schedule 13G and does not disclose related party transactions.
Stakeholder Impact
- Shareholders: Indicates a significant institutional investor group holds a substantial stake, potentially signaling confidence or strategic interest.
- Company Management: Awareness of a large, active shareholder group may influence strategic decisions.
Next Steps
- NA This filing is a Schedule 13G and does not outline future actions or milestones.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date as of which 7,207,792 shares of Common Stock were reported outstanding by the Issuer. |
| 06/30/2025 | Date of event requiring the filing of this statement, indicating the beneficial ownership threshold was met or changed. |
| 08/12/2025 | Date the Schedule 13G was signed by the Reporting Persons. |
Keywords
Silo Pharma, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, beneficial ownership, common stock, warrants, institutional investor, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.